| [1] |
Ostrom QT,Gittleman H,Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010[J].Neuro Oncol, 2013, 15 Suppl 2:ii1-56.
|
| [2] |
Zinn PO,Colen RR,Kasper EM, et al. Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients[J]. Int J Oncol, 2013, 42(3):929-934.
|
| [3] |
Darefsky AS,King JT,Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries[J]. Cancer, 2012, 118(8):2163-2172.
|
| [4] |
Morgan ER,Norman A,Laing K, et al. Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study[J]. Curr Oncol, 2017, 24(2):e92-e98.
|
| [5] |
Ostrom QT,Gittleman H,Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015, 17 Suppl 4:iv1-iv62.
|
| [6] |
Roa W,Xing JZ,Small C, et al. Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme[J]. Expert Rev Anticancer Ther, 2009, 9(11):1643-1650.
|
| [7] |
Buckner JC. Factors influencing survival in high-grade gliomas[J]. Semin Oncol, 2003, 30 (6 Suppl 19):10-14.
|
| [8] |
Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996.
|
| [9] |
Roh TH,Park HH,Kang SG, et al. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis[J]. Medicine (Baltimore), 2017, 96(27):e7422.
|
| [10] |
Filippini G,Falcone C,Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma[J]. Neuro Oncol, 2008, 10(1):79-87.
|
| [11] |
Hartmann C,Hentschel B,Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas[J]. Acta Neuropathol, 2010, 120(6):707-718.
|
| [12] |
Cohen AL,Holmen SL,Colman H. IDH1 and IDH2 mutations in gliomas[J]. Curr Neurol Neurosci Rep, 2013, 13(5):345.
|
| [13] |
Weller M,Platten M,Roth P, et al. Geriatric neuro-oncology: from mythology to biology[J]. Curr Opin Neurol, 2011, 24(6): 599-604.
|
| [14] |
Fiorentino A,Balducci M,De Bonis P, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials[J]? Am J Clin Oncol, 2015, 38(1): 23-27.
|
| [15] |
álvarez de Eulate-Beramendi S,álvarez-Vega MA,Balbin M, et al. Prognostic factors and survival study in high-grade glioma in the elderly[J]. Br J Neurosurg, 2016, 30(3):330-336.
|
| [16] |
Scott JG,Bauchet L,Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older[J]. Cancer, 2012, 118(22):5595-5600.
|
| [17] |
Young JS,Chmura SJ,Wainwright DA, et al. Management of glioblastoma in elderly patients[J]. J Neurol Sci, 2017, 380:250-255.
|
| [18] |
Zarnett OJ,Sahgal A,Gosio J, et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis[J]. JAMA Neurol, 2015, 72(5):589-596
|
| [19] |
Stupp R,Hegi ME,Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5):459-466.
|
| [20] |
Lasocki A,Gaillard F,Tacey M, et al. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival[J]. J Clin Neurosci, 2018, 47:168-173.
|
| [21] |
Hegi ME,Stupp R. Neuro-oncology: in search of molecular markers of glioma in elderly patients[J]. Nat Rev Neurol, 2013, 9(8):424-425.
|
| [22] |
Wiestler B,Claus R,Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective[J]. Neuro Oncol, 2013, 15(8):1017-1026.
|
| [23] |
Minniti G,Scaringi C,Lanzetta G, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1):109-115.
|
| [24] |
Hegi ME,Diserens AC,Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med, 2005, 352(10):997-1003.
|
| [25] |
Wainwright DA,Balyasnikova IV,Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival[J]. Clin Cancer Res, 2012, 18(22):6110-6121.
|
| [26] |
Reifenberger G,Hentschel B,Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly[J]. Int J Cancer, 2012, 131(6):1342-1350.
|
| [27] |
Batchelor TT,Betensky RA,Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma[J]. Clin Cancer Res, 2004, 10(1 Pt 1):228-233.
|
| [28] |
Chargari C,Feuvret L,Bauduceau O, et al. Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights[J]. Cancer Treat Rev, 2012, 38(8):988-995.
|
| [29] |
Ladomersky E,Zhai L,Gritsina G, et al. Advanced age negatively impacts survival in an experimental brain tumor model[J]. Neurosci Lett, 2016, 630:203-208.
|
| [30] |
Vuorinen V,Hinkka S,FärkkiläM, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study[J]. Acta Neurochir (Wien), 2003, 145(1):5-10.
|
| [31] |
Malmström A,Grønberg BH,Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(9):916-926.
|
| [32] |
Wick W,Platten M,Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial[J].Lancet Oncol, 2012, 13(7):707-715.
|
| [33] |
Rigamonti A,Imbesi F,Silvani A, et al. Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia hospitals[J]. Neuro Sci, 2017, 378:3-8.
|
| [34] |
Almenawer SA,Badhiwala JH,Alhazzani W, et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis[J]. Neuro Oncol, 2015, 17(6):868-881.
|
| [35] |
Babu R,Komisarow JM,Agarwal VJ, et al. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival[J]. J Neurosurg, 2016, 124(4):998-1007.
|
| [36] |
Chaichana KL,Chaichana KK,Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival.Clinical article[J]. J Neurosurg, 2011, 114(3):587-594.
|
| [37] |
Tanaka S,Meyer FB,Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients[J]. J Neurosurg, 2013, 118(4):786-798.
|
| [38] |
Keime-Guibert F,Chinot O,Taillandier L, et al. Radiotherapy for glioblastoma in the elderly[J]. N Engl J Med, 2007, 356(15): 1527-1535.
|
| [39] |
Scott J,Tsai YY,Chinnaiyan P, et al. Effectiveness of radiotherapy for elderly patients with glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1):206-210.
|
| [40] |
Roa W,Brasher PM,Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial[J]. J Clin Oncol, 2004, 22(9):1583-1588.
|
| [42] |
Gállego Pérez-Larraya J,Ducray F,Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial[J]. J Clin Oncol, 2011, 29(22):3050-3055.
|
| [43] |
Binabaj MM,Bahrami A,ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials[J]. J Cell Physiol, 2018, 233(1):378-386.
|
| [44] |
Chang-Halpenny CN,Yeh J,Lien WW. Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy[J]. The Permanente Journal, 2015, 19(1):15-20.
|
| [45] |
Yin AA,Cai S,Dong Y, et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients[J]. J Neurooncol, 2014, 116(2):315-324.
|
| [46] |
Huang J,Samson P,Perkins SM, et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base[J]. J Neurooncol, 2017, 131(3):593-601.
|
| [47] |
Metcalfe E,Karaoglanoglu O,Akyazici E. Radiotherapy with or without temozolomide in elderly patients aged≥70 years with glioblastoma[J]. Contemp Oncol (Pozn), 2016, 20(3):251-255.
|
| [48] |
Greer L,Pannullo SC,Smith AW, et al. Accelerated hypofractionated radiotherapy in the era of concurrent temozolomide chemotherapy in elderly patients with glioblastoma multiforme[J]. Cureus, 2017, 9(6):e1388.
|
| [49] |
Perry JR,Laperriere N,O'Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma[J]. N Engl J Med, 2017, 376(11):1027-1037.
|
| [50] |
Dunn-Pirio AM,Vlahovic G. Immunotherapy approaches in the treatment of malignant brain tumors[J].Cancer, 2017, 123(5):734-750.
|